• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, May 30 Dabur Pharma on Friday reported a net loss of Rs 87 lakh for the quarter ended March 31, 2008 compared with a year-ago profit of Rs 272 lakh. The drug maker lost revenue after it sold off its non-oncology business to Alembic. An appreciating Rupee against the dollar may also be responsible for the losses during the quarter.

Dabur, now controlled by German healthcare group Fresenius SE, earns 70 per cent of its revenue from the US and Europe. Total sales fell to Rs 46.6 crore from Rs 57.8 crore during the corresponding quarter last year.

Dabur shares were unchanged at Rs 73 on the Bombay Stock Exchange.

Commenting on the 2007-08 full-year results, Mr Ajay Kumar Vij, CEO, Dabur Pharma Ltd, said, “FY 2007-08 has been a good year for the company. It was the first full year of operations as a pure oncology player and the focus has started yielding positive results which is clearly visible in the excellent Oncology Formulations growth. This coupled with the major investments that we have been making in research and international market development will ensure that the growth momentum is aptly maintained well into the future.”

More Stories on : Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Dabur reports Q4 losses

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line